Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Judith Lind, Felix Czernilofsky, Sonia Vallet & Klaus Podar. (2019) Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs 24:3, pages 133-152.
Read now
Read now
Jianfeng Guo, Sharon L McKenna, Michael E O’Dwyer, Mary R Cahill & Caitriona M O’Driscoll. (2016) RNA interference for multiple myeloma therapy: targeting signal transduction pathways. Expert Opinion on Therapeutic Targets 20:1, pages 107-121.
Read now
Read now
Articles from other publishers (37)
Masahiro Hitomi, Juan Venegas, Shin Chung Kang & Charis Eng. (2023) Differential cell cycle checkpoint evasion by PTEN germline mutations associated with dichotomous phenotypes of cancer versus autism spectrum disorder. Oncogene 42:50, pages 3698-3707.
Crossref
Crossref
Young Yun Jung, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, Jae‐Young Um, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Kanchugarakoppal S. Rangappa & Kwang Seok Ahn. (2022) Brucein D imparts a growth inhibitory effect in multiple myeloma cells by abrogating the Akt‐driven signaling pathway. IUBMB Life 75:2, pages 149-160.
Crossref
Crossref
Hugh Kikuchi, Eunice Amofa, Maeve Mcenery, Steve Arthur Schey, Karthik Ramasamy, Farzin Farzaneh & Yolanda Calle. (2023) Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics. Cancers 15:2, pages 462.
Crossref
Crossref
Mark W. Nachtigal, Alon D. Altman, Rajat Arora, Frank Schweizer & Gilbert Arthur. (2022) The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer. Cancers 14:14, pages 3318.
Crossref
Crossref
Dominique B. Hoelzinger, Sophia J. Quinton, Denise K. Walters, Trupti Vardam-Kaur, Renee C. Tschumper, Henrique Borges da Silva & Diane F. Jelinek. (2022) Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology. Blood Advances 6:11, pages 3458-3471.
Crossref
Crossref
Laura O. Walter, Mariana F. Maioral, Lisandra O. Silva, Douglas B. Speer, Sanjay C. Campbell, Winklet Gallimore, Miriam B. Falkenberg & Maria Cláudia Santos‐Silva. (2022)
Involvement of the
NF‐κB
and
PI3K
/Akt/
mTOR
pathways in cell death triggered by stypoldione, an o‐quinone isolated from the brown algae
Stypopodium zonale
. Environmental Toxicology 37:6, pages 1297-1309.
Crossref
Crossref
Yan Zhou, Zirui Hong, Keting Jin, Chenjun Lin, Jingjing Xiang, Hangping Ge, Zhiyin Zheng, Jianping Shen & Shu Deng. (2022) Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway. Experimental and Therapeutic Medicine 24:1.
Crossref
Crossref
Barbara Manfredi, Jeffrey D. Neighbors & Raymond J. Hohl. (2022) Cytotoxic Effects of the Schweinfurthin Analog 5′-Methylschweinfurthin G in Malignant Plasma Cells. Pharmacology 107:9-10, pages 510-523.
Crossref
Crossref
Emilie Logie, Claudina Perez Novo, Amber Driesen, Pieter Van Vlierberghe & Wim Vanden Berghe. (2021) Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells. International Journal of Molecular Sciences 22:23, pages 12731.
Crossref
Crossref
Baocheng Gong, Jinhua Zhang, Zhongyan Hua, Zhihui Liu, Carol J. Thiele & Zhijie Li. (2021) Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells. Frontiers in Oncology 11.
Crossref
Crossref
Lukas John, Maria Theresa Krauth, Klaus Podar & Marc-Steffen Raab. (2021) Pathway-Directed Therapy in Multiple Myeloma. Cancers 13:7, pages 1668.
Crossref
Crossref
Monika Podhorecka. (2021) Metformin - its anti-cancer effects in hematologic malignancies. Oncology Reviews 15:1.
Crossref
Crossref
Meenakshisundaram Balasubramaniam, Naga Rajiv Lakkaniga, Ayed A Dera, Majed Al Fayi, Mohammed Abohashrh, Irfan Ahmad, Harish C. Chandramoorthy, Ganesan Nalini & Prasanna Rajagopalan. (2020) FCX‐146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second‐generation arylidene indanone scaffold. Biotechnology and Applied Biochemistry 68:1, pages 82-91.
Crossref
Crossref
Xiaohua Zhang & Shan Zhong. (2020) PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway. Anti-Cancer Agents in Medicinal Chemistry 20:7, pages 828-833.
Crossref
Crossref
Paul G. Richardson, Arnon Nagler, Dina Ben‐Yehuda, Ashraf Badros, Parameswaran N. Hari, Roman Hajek, Ivan Spicka, Hakan Kaya, Richard LeBlanc, Sung‐Soo Yoon, Kihyun Kim, Joaquin Martinez‐Lopez, Moshe Mittelman, Ofer Shpilberg, Paul Blake, Teru Hideshima, Kathleen Colson, Jacob P. Laubach, Irene M. Ghobrial, Merav Leiba, Moshe E. Gatt, Peter Sportelli, Michael Chen & Kenneth C. Anderson. (2020) Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. eJHaem 1:1, pages 94-102.
Crossref
Crossref
Ziquan Lv & Yajie Guo. (2020) Metformin and Its Benefits for Various Diseases. Frontiers in Endocrinology 11.
Crossref
Crossref
Xi Huang, Huiyao Gu, Enfan Zhang, Qingxiao Chen, Wen Cao, Haimeng Yan, Jing Chen, Li Yang, Ning Lv, Jingsong He, Qing Yi & Zhen Cai. (2019) The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma. International Journal of Cancer 146:7, pages 1963-1978.
Crossref
Crossref
Po Hu, Hui Li, Xiaoxuan Yu, Xiao Liu, Xiangyuan Wang, Yingjie Qing, Zhanyu Wang, Hongzheng Wang, Mengyuan Zhu, Jingyan Xu, Renxiang Tan, Qinglong Guo & Hui Hui. (2019) GL-V9 exerts anti-T cell malignancies effects via promoting lysosome-dependent AKT1 degradation and activating AKT1/FOXO3A/BIM axis. Free Radical Biology and Medicine 145, pages 237-249.
Crossref
Crossref
Ferda Kaleağasıoğlu, Maya M. Zaharieva, Spiro M. Konstantinov & Martin R. Berger. (2019) Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy. Anti-Cancer Agents in Medicinal Chemistry 19:1, pages 66-91.
Crossref
Crossref
Po-Jen Chen, I-Ling Ko, Chia-Lin Lee, Hao-Chun Hu, Fang-Rong Chang, Yang-Chang Wu, Yann-Lii Leu, Chih-Ching Wu, Cheng-Yu Lin, Chang-Yu Pan, Yung-Fong Tsai & Tsong-Long Hwang. (2019) Targeting allosteric site of AKT by 5,7-dimethoxy-1,4-phenanthrenequinone suppresses neutrophilic inflammation. EBioMedicine 40, pages 528-540.
Crossref
Crossref
He Huang, Xiao-ji Lin, Ying Lin, Ron-xin Yao & Mu-qing He. (2017) Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation. Indian Journal of Hematology and Blood Transfusion 34:2, pages 268-272.
Crossref
Crossref
Maria C. Ramello, Eric B. Haura & Daniel Abate-Daga. (2018) CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?. Pharmacological Research 129, pages 194-203.
Crossref
Crossref
Ademar Dantas Cunha Júnior, Fernando Vieira Pericole & Jose Barreto Campello Carvalheira. (2018) Metformin and blood cancers. Clinics 73, pages e412s.
Crossref
Crossref
Nurulhuda Mustafa, Jeannie Xue Ting Lee, Huey Fang Adina Nee, Chonglei Bi, Tae-Hoon Chung, Stefan Hart & Wee Joo Chng. (2017) VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. Oncotarget 8:60, pages 101847-101864.
Crossref
Crossref
Ru-Fang Xiang, Yan Wang, Nan Zhang, Wen-Bin Xu, Yang Cao, Jia Tong, Jun-min Li, Ying-Li Wu & Hua Yan. (2017) MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death & Disease 8:5, pages e2776-e2776.
Crossref
Crossref
Yi Tao, Guang Yang, Hongxing Yang, Dongliang Song, Liangning Hu, Bingqian Xie, Houcai Wang, Lu Gao, Minjie Gao, Hongwei Xu, Zhijian Xu, Xiaosong Wu, Yiwen Zhang, Weiliang Zhu, Fenghuang Zhan & Jumei Shi. (2017) TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget 8:16, pages 26718-26731.
Crossref
Crossref
Natsuki Imayoshi, Makoto Yoshioka, Jay Chauhan, Susumu Nakata, Yuki Toda, Steven Fletcher, Jeffrey W. Strovel, Kazuyuki Takata & Eishi Ashihara. (2017) CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model. Biochemical and Biophysical Research Communications 484:2, pages 262-268.
Crossref
Crossref
Sabrina Manni, Marilena Carrino, Martina Manzoni, Ketty Gianesin, Sara Canovas Nunes, Matteo Costacurta, Laura Quotti Tubi, Paolo Macaccaro, Elisa Taiana, Anna Cabrelle, Gregorio Barilà, Annalisa Martines, Renato Zambello, Laura Bonaldi, Livio Trentin, Antonino Neri, Gianpietro Semenzato & Francesco Piazza. (2017) Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways. Oncotarget 8:9, pages 14604-14619.
Crossref
Crossref
Rimda Wanchoo, Ala Abudayyeh, Mona Doshi, Amaka Edeani, Ilya G. Glezerman, Divya Monga, Mitchell Rosner & Kenar D. Jhaveri. (2017) Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clinical Journal of the American Society of Nephrology 12:1, pages 176-189.
Crossref
Crossref
Hanley N. Abramson. (2016) Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget 7:49, pages 81926-81968.
Crossref
Crossref
Leonard Naymagon & Maher Abdul-Hay. (2016) Novel agents in the treatment of multiple myeloma: a review about the future. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Gabriela Rozic, Lena Paukov, Jana Jakubikova, Dikla Ben-Shushan, Adrian Duek, Adi Leiba, Abraham Avigdor, Arnon Nagler & Merav Leiba. (2016)
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma
in vitro
and
in vivo
. Oncotarget 7:38, pages 62572-62584.
Crossref
Crossref
Masahiro Kizaki & Takayuki Tabayashi. (2016) The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches. Journal of Clinical and Experimental Hematopathology 56:1, pages 20-27.
Crossref
Crossref
Robert M. Garbaccio & Emma R. Parmee. (2016) The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective. Cell Chemical Biology 23:1, pages 10-17.
Crossref
Crossref
Naoya Mimura, Teru Hideshima & Kenneth C. Anderson. (2015) Novel therapeutic strategies for multiple myeloma. Experimental Hematology 43:8, pages 732-741.
Crossref
Crossref
Jingjing Chen, Xiangyuan Bu & Qi Shen. (2015) Enhanced anti‐cancer activity by co‐delivery of docetaxel and perifosine with multifunctional nanoparticles via regulation of PI3K/Akt signalling pathway. Micro & Nano Letters 10:5, pages 253-257.
Crossref
Crossref
Stefan Hausmann, Evelyn Brandt, Carolin Köchel, Hermann Einsele, Ralf C. Bargou, Ruth Seggewiss-Bernhardt & Thorsten Stühmer. (2015) Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines. PLOS ONE 10:4, pages e0122689.
Crossref
Crossref